Hypertrophy and fibrosis in the cardiomyopathy of uremia--beyond coronary heart disease.
about
Uremic Toxins - Novel Arrhythmogenic Factor in Chronic Kidney Disease - Related Atrial FibrillationLeft Ventricular Hypertrophy in Chronic Kidney Disease Patients: From Pathophysiology to Treatment.Heart failure in patients with chronic kidney disease: a systematic integrative reviewCulture-modified bone marrow cells attenuate cardiac and renal injury in a chronic kidney disease rat model via a novel antifibrotic mechanismSpeckle tracking echocardiography detects uremic cardiomyopathy early and predicts cardiovascular mortality in ESRD.Recurrent intradialytic paroxysmal atrial fibrillation: hypotheses on onset mechanisms based on clinical data and computational analysis.Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sulfate.Curcumin prevents cardiac remodeling secondary to chronic renal failure through deactivation of hypertrophic signaling in rats.Electrocardiographic left ventricular hypertrophy and outcome in hemodialysis patients.Association of versican turnover with all-cause mortality in patients on haemodialysis.ADPKD: Prototype of Cardiorenal Syndrome Type 4Rationale and design of the Sodium Lowering In Dialysate (SoLID) trial: a randomised controlled trial of low versus standard dialysate sodium concentration during hemodialysis for regression of left ventricular mass.Association of systemic collagen type IV formation with survival among patients undergoing hemodialysis.Soluble Klotho Protects against Uremic Cardiomyopathy Independently of Fibroblast Growth Factor 23 and Phosphate.Randomized Controlled Trial of Individualized Dialysate Cooling for Cardiac Protection in Hemodialysis PatientsSerum potassium and cause-specific mortality in a large peritoneal dialysis cohortUpdate on fibroblast growth factor 23 in chronic kidney disease.Predictors of Arrhythmic Events Detected by Implantable Loop Recorders in Renal Transplant Candidates.Effect of a plasma sodium biofeedback system applied to HFR on the intradialytic cardiovascular stability. Results from a randomized controlled studyCardiac Biomarkers and Left Ventricular Hypertrophy in Asymptomatic Hemodialysis Patients.Characterisation of cardiomyopathy by cardiac and aortic magnetic resonance in patients new to hemodialysisDefining myocardial tissue abnormalities in end-stage renal failure with cardiac magnetic resonance imaging using native T1 mapping.Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufageninArrhythmic complication in cardiorenal syndrome.Experimental models of renal disease and the cardiovascular system.Cardiorenal syndrome: pathophysiology, preclinical models, management and potential role of uraemic toxins.Using dialysis machine technology to reduce intradialytic hypotension.Blood pressure and blood volume: acute and chronic considerations in hemodialysis.Cardiorenal syndrome: acute kidney injury secondary to cardiovascular disease and role of protein-bound uraemic toxins.Is left ventricular hypertrophy a modifiable risk factor in end-stage renal disease.Clinical Outcomes in Dialysis Patients: Prospects for Improvement with Aldosterone Receptor Antagonists.The importance of accurate measurement of aortic stiffness in patients with chronic kidney disease and end-stage renal disease.Why Is Your Patient Still Short of Breath? Understanding the Complex Pathophysiology of Dyspnea in Chronic Kidney Disease.Cardiac actions of fibroblast growth factor 23.Cardiovascular impact in patients undergoing maintenance hemodialysis: Clinical management considerations.Renal dysfunction and diastolic impairment among British ethnic minorities with hypertension: the Ethnic-Echocardiographic Heart of England Screening Study.αKlotho and Chronic Kidney Disease.New Insights into the Mechanism of Action of Soluble Klotho.Chronic Kidney Disease and Disproportionally Increased Cardiovascular Damage: Does Oxidative Stress Explain the Burden?Magnetic resonance tissue phase mapping demonstrates altered left ventricular diastolic function in children with chronic kidney disease.
P2860
Q26747869-AA007604-77C2-4910-8580-D5E77B3D680DQ26773120-9A227767-39FD-4ED8-97DF-D21E8CE11CDCQ26824149-8E551389-BFFD-4B6D-B969-232C56D9E473Q27333630-B597280C-79E7-4BCB-8D02-C1C14189909DQ30401905-6E1E61CD-BA48-40E0-A5BE-652B1E4B1C42Q30764530-0E47BAAE-B6ED-4408-9C96-D189FC471CF3Q31076633-339624E3-EA02-4D10-8044-0842FA7327B2Q34212259-28C26114-98AD-45E1-9FC5-D856DD38EA65Q34243856-29990028-26D1-4A89-9114-FA653D022ED2Q34420828-1C1110FC-D2D2-4FC9-8D03-CE0882B116DCQ34475590-B160906D-6498-4433-A459-647EC9B5AD87Q34820403-782684E4-91E3-4E4E-9E24-B319740EF2D7Q34976972-7B585E42-17CA-450B-B0AB-BE25F3C21EFFQ35550609-A2B0904F-F732-4A41-858E-2B59372187BBQ35922682-E943CBD1-A999-4A58-92A4-4535C30C9440Q36126907-E22C2549-B6CC-4C09-87A5-D4F7D8816C44Q36210285-F71E357B-C5DB-46E2-8D89-54E36EF338C0Q36295799-0C189644-6011-4A22-AEF6-91A3FDBC7403Q36358756-F93C405B-C46E-4F93-A24D-C36835920E29Q36945030-E6269602-AA63-4C01-A716-FA16D04F6615Q37053525-B14FA7AA-60E7-4AB4-9D74-0B6BAE600B32Q37280134-A7A3D64C-533A-438E-9FED-064D18DAF805Q37438192-CC5042B8-7A35-490C-B704-1DA485BC885DQ37813471-33BD3523-B534-4AEE-8F54-2F1BA74E7715Q37831804-63C2F713-5BB1-491B-AD6E-4837CCFD5E40Q37947677-2783A7B7-0A73-4A61-80F2-BC44F67D8F2CQ37957419-3C3856A4-2D65-4666-8739-927A5B73115EQ38045940-9281A06C-9594-4E47-B56F-799EA40A2F3CQ38218395-EE44AED0-E292-491D-A70E-87F047AD7B32Q38258133-0CB7D1E9-1F1A-49A0-8ED7-0E09E267E8A6Q38560705-E42CE5DC-9207-45DB-B1B8-F80FB5B14F28Q38635835-8CC7148C-C296-4DA8-A5BA-829700468619Q38966893-F85A0644-AF4A-4F20-BC36-E2E1E118D952Q38977291-E735A5C3-0DD0-402D-BC3F-6EE4DED6ED1FQ39096879-6707608F-7AB5-49A4-880E-6B4456C10251Q39413144-978DD3A4-71E4-40B5-B8D5-3B206C8338D0Q39812781-3A259256-E098-4B5F-A6ED-DBAE32331284Q47132894-1421E7DA-DB55-4BFE-BE09-CAFA778DB191Q47732797-2A8EF2B3-BE77-4CDF-8D8E-BB4F7FBB1708Q48158317-5904E891-D336-4A3E-909A-6A5F700B25C8
P2860
Hypertrophy and fibrosis in the cardiomyopathy of uremia--beyond coronary heart disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Hypertrophy and fibrosis in the cardiomyopathy of uremia--beyond coronary heart disease.
@en
Hypertrophy and fibrosis in the cardiomyopathy of uremia--beyond coronary heart disease.
@nl
type
label
Hypertrophy and fibrosis in the cardiomyopathy of uremia--beyond coronary heart disease.
@en
Hypertrophy and fibrosis in the cardiomyopathy of uremia--beyond coronary heart disease.
@nl
prefLabel
Hypertrophy and fibrosis in the cardiomyopathy of uremia--beyond coronary heart disease.
@en
Hypertrophy and fibrosis in the cardiomyopathy of uremia--beyond coronary heart disease.
@nl
P2860
P1433
P1476
Hypertrophy and fibrosis in the cardiomyopathy of uremia--beyond coronary heart disease.
@en
P2093
Eberhard Ritz
Marie-Luise Gross
P2860
P304
P356
10.1111/J.1525-139X.2008.00454.X
P577
2008-07-08T00:00:00Z